Treating to target with etanercept in rheumatoid arthritis: Cost-effectiveness of dose reductions when remission is achieved

Value in Health

Volumn 17, Issue 5, 2014, Pages 537-544

  Kobelt, Gisela ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b European Health Economics   (France)

Author keywords

cost effectiveness; etanercept; modeling; remission; rheumatoid arthritis

Indexed keywords

ETANERCEPT; METHOTREXATE;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG DOSE REDUCTION; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS;

COST-EFFECTIVENESS; ETANERCEPT; MODELING; REMISSION; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOGLOBULIN G; MARKOV CHAINS; METHOTREXATE; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES; REMISSION INDUCTION; SWEDEN; TREATMENT OUTCOME;

EID: 84906273443     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2014.04.005     Document Type: Article

References (23)

1. JS Smolen, R Landewe, and FC Breedveld et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs Ann Rheum Dis 69 2010 964 975
2. DE Furst, EC Keystone, and J Braun et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011 Ann Rheum Dis 2012;71 Suppl. 2 2012 i2-45
3. B Combe, R Landewe, and C Lukas et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) Ann Rheum Dis 66 2007 34 45
4. JS Smolen, D Aletaha, and JW Bijlsma et al. Treating rheumatoid arthritis to target: recommendations of an international task force Ann Rheum Dis 69 2010 631 637
5. FC Breedveld, MH Weisman, and AF Kavanaugh et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment Arthritis Rheum 54 2006 26 37
6. P Emery, F Breedveld, and D van der Heijde et al. Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study Arthritis Rheum 62 2010 674 682
7. O Brocq, E Millasseau, and C Albert et al. Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis Joint Bone Spine 76 2009 350 355
8. C Botsios, A Furlan, and P Ostuni et al. Effects of low-dose etanercept in maintaining DAS-remission previously achieved with standard dose in patients with rheumatoid arthritis Ann Rheum Dis 66 2009 54
9. P Emery, TK Kvien, and B Combe et al. Combination etanercept and methotrexate provides better disease control in very early (<=4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study Ann Rheum Dis 71 2012 989 992
10. E Gremese, F Salaffi, and SL Bosello et al. Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study Ann Rheum Dis 72 6 2013 858 862
11. Kobelt G, Kasteng F. The burden of rheumatoid arthritis and access to new treatments. Available from: www.comparatorreports.se. [Accessed January 13, 2014].
12. G Kobelt, P Lindgren, and P. Geborek Costs and outcomes for patients with rheumatoid arthritis treated with biological drugs in Sweden: a model based on registry data Scand J Rheumatol 38 2009 409 418
13. G Kobelt, I Lekander, and A Lang et al. Cost-effectiveness of etanercept treatment in active early RA followed by dose adjustment Int J Technol Assess Health Care 27 2011 193 200
14. J Smolen, P Nash, and P Durez et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial Lancet 381 2013 918 929
15. L Klareskog, D van der Heijde, and JP de Jager et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial Lancet 363 2004 675 681
16. D Scott, K Pugner, and K Kaarela et al. The links between joint damage and disability in rheumatoid arthritis Rheumatology 39 2000 122 132
17. G Kobelt, P Lindgren, A Singh, and L. Klareskog Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial Ann Rheum Dis 64 2005 1174 1179
18. LT Jacobsson, Y Lindroth, and L Marsal et al. Rheumatoid arthritis: what does it cost and what factors are driving those costs? Results of a survey in a community-derived population in Malmo, Sweden Scand J Rheumatol 36 2007 179 183
19. G Kobelt, P Lindgren, and Y Lindroth et al. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis Rheumatology (Oxford) 44 2005 1169 1175
20. FASS Läkemedel i Sverige (Pharmaceutical Lexicon) 2011 Lakemedelsinformation AB Stockholm, Sweden
21. M Van den Broek, NB Klarenbeek, and L Dirven et al. Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study Ann Rheum Dis 70 8 2011 1389 1394
22. I Lekander, F Borgstrom, and P Svarvar et al. Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden Int J Technol Assess Health Care 26 2010 54 61
23. J Fries, P Spitz, R Kraines, and H. Holman Measurement of patient outcome in arthritis Arthritis Rheum 23 1980 137 145